Adverse effects and fatalities associated with subcutaneous allergen immunotherapy

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 455-468

  Bukantz, Samuel C ^a   Bagg, Andrew S ^a   Lockey, Richard F ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E;

ANAPHYLAXIS; BLOOD; DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; MORTALITY; REVIEW; RISK FACTOR; SKIN TEST; SUBCUTANEOUS DRUG ADMINISTRATION;

ALLERGENS; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; RISK FACTORS; SKIN TESTS;

EID: 58149460764     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (122)

1. Van Arsdel PP, Sherman WB. Risk of inducing constitutional reactions in allergic patients. J Allergy 1957; 28: 251-261.
2. Cooke RA, Veer AV. Human sensitization. J Immunol 1916; 1: 201-305.
3. Turkeltaub PC, Gergen PJ. The risk of adverse reactions from percutaneous prick-puncture allergen skin testing, venipuncture, and body measurements: data from the second National Health and Nutrition Examination Survey 1976-80 (NHANES II). J Allergy Clin Immunol 1989; 84: 886-890.
4. Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986; 77: 865-870.
5. Hejjaoui A, Dhivert H, Michel FB, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990; 85: 473-479.
6. Hepner M, Ownby D, MacKechnie H, et al. The safety of immunotherapy-a prospective study. J Allergy Clin Immunol 1987; 79:(133).
7. Levine MI. Systemic reactions to immunotherapy. J Allergy Clin Immunol 1979; 63: 209 (abstr).
8. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy 1986; 56: 331-334.
9. Osterballe O. Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982; 37: 553-562.
10. Rawlins MD, Wood SM, Mann RD. Hazards with desensitising vaccines. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1988; 82: 147-151.
11. Rieckenberg MR, Khan RH, Day JH. Physician reported patient response to immunotherapy: a retrospective study of factors affecting the response. Ann Allergy 1990; 64: 364-367.
12. Vervloet D, Khairallah E, Arnaud A, et al. A prospective national study of the safety of immunotherapy. Clin Allergy 1980; 10: 59-64.
13. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003; 90: 1-40.
14. Akcakaya N, Hassanzadeh A, Camcioglu Y, et al. Local and systemic reactions during immunotherapy with adsorbed extracts of house dust mite in children. Ann Allergy Asthma Immunol 2000; 85: 317-321.
15. Brockow K, Kiehn M, Riethmuller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebocontrolled trial. J Allergy Clin Immunol 1997; 100: 458-463.
16. Karaayvaz M, Erel F, Caliskaner Z, et al. Systemic reactions due to allergen immunotherapy. J Investig Allergol Clin Immunol 1999; 9: 39-44.
17. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, et al. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001; 87: 47-55.
18. Machin IS, Robaina JCG, Bonnet C, et al. Immunotherapy units: a follow-up study. J Investig Allergol Clin Immunol 2001; 11: 167-171.
19. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000; 23: 323-332.
20. Mellerup MT, Hahn GW, Poulsen LK, et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30: 1423-1429.
21. Nettis E, Giordano D, Pannofino A, et al. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy 2002; 32: 1745-1749.
22. Tankersley MS, Butler KK, Butler WK, et al. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106: 840-843.
23. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollenallergic rhinitis. II. Side-effects. Allergy 2000; 55: 827-835.
24. Wuthrich B, Gumowski PL, Fah J, et al. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide. J Investig Allergol Clin Immunol 2001; 11: 149-156.
25. Bhalla PL. Genetic engineering of pollen allergens for hayfever immunotherapy. Expert Rev Vaccines 2003; 2: 75-84.
26. Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev Vaccines 2002; 1: 265-276.
27. Di Gioacchino M, Cavallucci E, Di Sciascio MB, et al. Allergen immunotherapy: an effective immune-modifier. Int J Immunopathol Pharmacol 1999; 12: 1-5.
28. Holt PG, Rowe J, Loh R, et al. Developmental factors associated with risk for atopic disease: implications for vaccine strategies in early childhood. Vaccine 2003; 21: 3432-3435.
29. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. Curr Opin Allergy Clin Immunol 2003; 3: 159-164.
30. Reyes Moreno A, Castrejon Vazquez MI, Miranda Feria AJ. [Failure of allergen-based immunotherapy in adults with allergic asthma]. Rev Alerg Mex 2003; 50: 8-12.
31. Spiegelberg HL, Takabayashi K, Beck L, et al. DNA-based vaccines for allergic disease. Expert Rev Vaccines 2002; 1: 169-177.
32. Tarzi M, Larche M. Peptide immunotherapy for allergic disease. Expert Opin Biol Ther 2003; 3: 617-626.
33. Tella R, Bartra J, San Miguel M, et al. Effects of specific immunotherapy on the development of new sensitisations in monosensitised patients. Allergol Immunopathol (Madr) 2003; 31: 221-225.
34. Criado Molina A, Guerra Pasadas F, Daza Munoz JC, et al. [Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters]. Allergol Immunopathol (Madr) 2002; 30: 319-330.
35. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997; 100: 30-38.
36. Liu YH, Kao MC, Lai YL, et al. Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide. J Allergy Clin Immunol 2003; 112: 301-310.
37. Passali D, Bellussi L, Passali GC, et al. Nasal immunotherapy is effective in the treatment of rhinitis due to mite allergy. A double-blind, placebo-controlled study with rhinological evaluation. Int J Immunopathol Pharmacol 2002; 15: 141-147.
38. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131: 111-118.
39. Cirla AM, Cirla PE, Parmiani S, et al. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. Allergol Immunopathol (Madr) 2003; 31: 31-43.
40. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33: 206-210.
41. Grosclaude M, Bouillot P, Alt R, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002; 129: 248-253.
42. Passalacqua G, Baena-Cagnani CE, Berardi M, et al. Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol 2003; 3: 139-145.
43. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
44. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007; 7: 410-420.
45. Horner AA, Takabaysahi K, Zubeldia JM, et al. Immunostimulatory DNA-based therapeutics for experimental and clinical allergy. Allergy 2002; 57(suppl 72): 24-29.
46. Horner AA, Van Uden JH, Zubeldia JM, et al. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev 2001; 179: 102-118.
47. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
48. Lamson R. Death associated with injection of foreign substances. JAMA 1924; 82.
49. Vance BM, Strassman, G. Sudden death following injection of foreign protein. Arch Pathol 1942; 34: 849-865.
50. James LP Jr., Austen KF. Fatal systemic anaphylaxis in man. N Engl J Med 1964; 270: 597-603.
51. Sheppe WM. Fatal anaphylaxis in man. J Lab Clin Med 1930; 16: 372-375.
52. Blanton WV, Sutphin AK. Death during skin testing. Am J Med Sci 1949; 217: 169-173.
53. Rosenthal A. Fatal anaphylactic reactions to penicillin. NY State J Med 1954; 54: 1485-1487.
54. Rands DA. Anaphylactic reaction to desensitisation for allergic rhinitis and asthma. Br Med J 1980; 281: 854.
55. CSM Update: Desensitizing vaccines. Br Med J 1986; 293: 948.
56. Lü deritz-Puchel U. Haustein D. Incidents following hyposensitization. Mü nch med Wschr 1996; 138: 1-7.
57. Busse WW, Storms WW, Flaherty DK, et al. Alternaria IgG precipitins and adverse reactions. J Allergy Clin Immunol 1976; 57: 367-372.
58. Kaad PH, Ostergaard PA. The hazard of mould hyposensitization in children with asthma. Clin Allergy 1982; 12: 317-320.
59. Kemler BJ, Franklin WD, Alpert E, et al. Failure to detect circulating immune complexes in allergic patients on injection therapy. Clin Allergy 1979; 9: 473-478.
60. Stein MR, Brown GL, Lima JE, et al. A laboratory evaluation of immune complexes in patients on inhalant immunotherapy. J Allergy Clin Immunol 1978; 62: 211-216.
61. Cano PO, Chow M, Jerry LM, et al Circulating immune complexes in patients with atopic allergy. Clin Allergy 1977; 7: 167-171.
62. El-Hefny A, Ekladious EM, El-Sharkawy S, et al. Extrinsic allergic bronchiolo-alveolitis in children. Clin Allergy 1980; 10: 651-658.
63. Kuuliala O, Palosuo T, Aho K, et al. Haemagglutinating antibodies to cat dander in relation to exposure and respiratory allergy. Clin Allergy 1979; 9: 391-395.
64. Moore VL, Fink JN. Immunologic studies in hypersensitivity pneumonitis-quantitative precipitins and complement-fixing antibodies in symptomatic and asymptomatic pigeon breeders. J Lab Clin Med 1975; 85: 540-545.
65. Stendardi L, Delespesse G, Debisschop MJ. Circulating immune complexes in bronchial asthma. Clin Allergy 1980; 10: 405-411.
66. Clausen RW, Yanari SS. Immune complex-mediated disease not a factor in patients on maintenance venom immunotherapy. J Allergy Clin Immunol 1983; 72: 199-203.
67. Umetsu DT, Hahn JS, Perez-Atayde AR, et al. Serum sickness triggered by anaphylaxis: a complication of immunotherapy. J Allergy Clin Immunol 1985; 76: 713-718.
68. Clemmensen O, Knudsen HE. Contact sensitivity to aluminium in a patient hyposensitized with aluminium precipitated grass pollen. Contact Dermatitis 1980; 6: 305-308.
69. Wolpow ER. Brachial plexus neuropathy. Association with desensitizing antiallergy injections. JAMA 1975; 234: 620-621.
70. Schatz M, Patterson R, DeSwarte R. Nonorganic adverse reactions to aeroallergen immunotherapy. J Allergy Clin Immunol 1976; 58: 198-203.
71. Bokisch VA, Bernstein D, Krause RM. Occurrence of 19S and 7S anti-IgGs during hyperimmunization of rabbits with streptococci. J Exp Med 1972; 136: 799-815.
72. Christian CL, Desimone AR, Abruzzo JL. Anti-DNA antibodies in hyperimmunized rabbits. J Exp Med 1965; 121: 309-321.
73. Eichmann K, Braun DG, Krause RM. Influence of genetic factors on the magnitude and the heterogeneity of the immune response in the rabbit. J Exp Med 1971; 134: 48-65.
74. Potter M. Myeloma proteins (M-components) with antibody-like activity. N Engl J Med 1971; 284: 831-838.
75. Riesen W, Rudikoff S, Oriol R, et al. An IgM Waldenstrom with specificity against phosphorylcholine. Biochemistry 1975; 14: 1052-1057.
76. Penny R, Hughes S. Repeated stimulation of the reticuloendothelial system and the development of plasma-cell dyscrasias. Lancet 1970; 1: 77-78.
77. Raphael SA, Nell PA, Hymchuk, Lischner HW. Positive late antiglobulin test in atopic pediatric subjects receiving hyposensitization therapy. J Allergy Clin Immunol 1976; 57: 231.
78. Levinson AI, Summers RJ, Lawley TJ, et al. Evaluation of the adverse effects of long-term hyposensitization. J Allergy Clin Immunol 1978; 62: 109-114.
79. Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980; 68: 479-485.
80. McCombs CC, Michalski JP, Jerome DC. Case 26-1980: pemphigus vulgaris after hyposensitization injections. N Engl J Med 1980; 303: 1179.
81. Katelaris CH, Walls RS. A study of possible ill effects from prolonged immunotherapy in treatment of allergic diseases. Ann Allergy 1984; 53: 257-261.
82. Waldbott GL. The prevention of anaphylactic shock. JAMA 1932; 98: 446-449.
83. Vaughan VA, Black JR. Practice of Allergy. St. Louis: C. V. Mosby, 1939.
84. Pollard RCH. Anaphylactic reaction to desensitization. Br Med J 1980; 281: 481.
85. Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79: 660-677.
86. Baagoe K. Case of allergic death due to intracutaneous injection of 10 cc of white of hen’s egg. Ugeskr Laeger 1928; 90: 550.
87. Wiseman J, McCarthy-Brough MP. Skin sensitivity in the aged-fatality following intradermal tests. J Allergy 1945; 16: 250.
88. Swineford O. Anaphylactic shock from skin testing. J Allergy 1946; 17: 24.
89. Blanton WB, Sutphin AK. Death during skin testing. Am J Med Sci 1949; 217: 169-173.
90. Harris MC, Shure N. Sudden death due to allergy tests. J Allergy 1950; 21: 208-216.
91. Dogliotti M. An instance of fatal reaction to the penicillin scratch-test. Dermatologica 1968; 136: 489-496.
92. Reid M, Gurka G. Deaths associated with skin testing and immunotherapy. J Allergy Clin Immunol 1996; 97: 231.
93. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004: 1129-1136.
94. Waldbatt GL. The prevention of anaphylactic shock. JAMA 1932; 98: 446.
95. Reid MJ, Lockey RF, Turkeltaub PC, et al. Fatalities (F) from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1990; 85.
96. Reid MJ, Lockey RF, Turkeltaub PC, et al. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92: 6-15.
97. Norman PS. Fatal misadventures. J Allergy Clin Immunol 1987; 79: 572-573.
98. National Disease and Therapeutic Index. Plymouth Meeting, PA: IMS America Ltd., 1978-1988.
99. Lockey RF, Turkeltaub PC, Olive CA, et al. The Hymenoptera venom study II: Skin test results and safety of venom skin testing. J Allergy Clin Immunol 1989; 84: 967-974.
100. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86: 775-780.
101. Lin MS, Tanner E, Lynn J, et al. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71: 557-562.
102. Liccardi G, Salzillo A, Spadaro G, et al. Anaphylaxis caused by skin prick testing with aeroallergens: case report and evaluation of the risk in Italian allergy services. J Allergy Clin Immunol 2003; 111: 1410-1412.
103. Valyasevi MA, Maddox DE, Li JT. Systemic reactions to allergy skin tests. Ann Allergy Asthma Immunol 1999; 83: 132-136.
104. Thompson M, Shearer D, Lockey R, et al. Systemic reactions to percutaneous (P) and intradermal (ID) skin tests (ST). J Allergy Clin Immunol 1998; 101: S30.
105. Bagg A, Chacko T, Glaum M, et al. Systemic reactions to percutaneous and intradermal skin tests. World Allergy Congress. Bangkok, Thailand, December, 2007.
106. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117: 169-175.
107. Ragusa FV, Passalacqua G, Gambardella R, et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol 1997; 7: 151-154.
108. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg Immunol (Paris) 2004; 36: 52-55.
109. Stewart E, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90: 567-578.
110. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96: 600-605.
111. Berchtold E, Maibach R, Muller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 22: 59-65.
112. Nielsen L, Johnsen CR, Mosbech H, et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996; 97: 1207-1213.
113. Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994; 73: 409-418.
114. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117: 134-140.
115. Portnoy J, Bagstad K, Kanarek H, et al. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120: S25-S85.
116. Casale TB, Busse WW, Kline JN, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseas. Geneva: January 27-29, 1997. Allergy 1998; 53: 1-42.
117. Kaplan AP, Anderson JA, Valentine MD, et al. Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology. J Allergy Clin Immunol 1989; 84: 129-130.
118. Bousquet J, Hejjaoui A, Dhivert H, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989; 83: 797-802.
119. Norman PS, Van Metre TE Jr. The safety of allergenic immunotherapy. J Allergy Clin Immunol 1990; 85: 522-525.
120. Bousquet J, Hejjaoui A, Dhivert H, et al. Personnel and equipment to treat systemic reactions caused by immunotherapy with allergenic extracts. American Academy of Allergy and Immunology. J Allergy Clin Immunol 1986; 77: 271-273.
121. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 401-405.
122. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110: 341-348.